High Prognostic Value of <sup>68</sup>Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry
In oligo-metastatic renal cell carcinoma (RCC), neither computed tomography (CT) nor bone scan is sensitive enough to detect small tumor deposits hampering early treatment and potential cure. Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein expressed in the neo-vasculature o...
| Published in: | Diagnostics |
|---|---|
| Main Authors: | Donatello Gasparro, Maura Scarlattei, Enrico Maria Silini, Silvia Migliari, Giorgio Baldari, Veronica Cervati, Tiziano Graziani, Nicoletta Campanini, Umberto Maestroni, Livia Ruffini |
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/19/3082 |
Similar Items
Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System
by: Zsófia Sára Mikó, et al.
Published: (2024-10-01)
by: Zsófia Sára Mikó, et al.
Published: (2024-10-01)
<sup>68</sup>Ga-PSMA PET/CT in Recurrent Prostate Cancer after Radical Prostatectomy Using PSMA-RADS Version 2.0
by: Gabriele Masselli, et al.
Published: (2024-06-01)
by: Gabriele Masselli, et al.
Published: (2024-06-01)
PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression
by: Florian Rosar, et al.
Published: (2022-05-01)
by: Florian Rosar, et al.
Published: (2022-05-01)
[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2021-07-01)
by: Ute Hennrich, et al.
Published: (2021-07-01)
Imageological/Structural Study regarding the Improved Pharmacokinetics by <sup>68</sup>Ga-Labeled PEGylated PSMA Multimer in Prostate Cancer
by: Huihui Zhang, et al.
Published: (2023-04-01)
by: Huihui Zhang, et al.
Published: (2023-04-01)
Multimodal Characterization of a PSMA-Positive Thyroid Nodule Using <sup>68</sup>Ga-PSMA and <sup>124</sup>Iodine PET/US Fusion Imaging
by: Martin Freesmeyer, et al.
Published: (2022-02-01)
by: Martin Freesmeyer, et al.
Published: (2022-02-01)
Feasibility of biology-guided radiotherapy for metastatic renal cell carcinoma driven by PSMA PET imaging
by: Mathieu Gaudreault, et al.
Published: (2023-05-01)
by: Mathieu Gaudreault, et al.
Published: (2023-05-01)
Parathyroid Adenoma Detected in <sup>68</sup>Ga-PSMA PET/CT but Not in the Dedicated Imaging Modalities
by: Maja Cieślewicz, et al.
Published: (2024-08-01)
by: Maja Cieślewicz, et al.
Published: (2024-08-01)
Analysis of Pros and Cons in Using [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>18</sup>F]PSMA-1007: Production, Costs, and PET/CT Applications in Patients with Prostate Cancer
by: Costantina Maisto, et al.
Published: (2022-06-01)
by: Costantina Maisto, et al.
Published: (2022-06-01)
Prostate Cancer Biochemical Recurrence Resulted Negative on [<sup>68</sup>Ga]Ga-PSMA-11 but Positive on [<sup>18</sup>F]Fluoromethylcholine PET/CT
by: Riccardo Laudicella, et al.
Published: (2022-09-01)
by: Riccardo Laudicella, et al.
Published: (2022-09-01)
Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study)
by: Salma Binzaqr, et al.
Published: (2025-04-01)
by: Salma Binzaqr, et al.
Published: (2025-04-01)
Total Tumor Volume on <sup>18</sup>F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with <sup>225</sup>Ac-PSMA-I&T
by: Lena M. Unterrainer, et al.
Published: (2022-04-01)
by: Lena M. Unterrainer, et al.
Published: (2022-04-01)
Active Lumbar Spondylodiscitis on [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT Mimicking Bone Metastasis
by: Florian Rosar, et al.
Published: (2023-12-01)
by: Florian Rosar, et al.
Published: (2023-12-01)
Dependence of Renal Uptake on Kidney Function in [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT Imaging
by: Falk Gühne, et al.
Published: (2024-03-01)
by: Falk Gühne, et al.
Published: (2024-03-01)
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
by: Catherine Meyer, et al.
Published: (2022-10-01)
by: Catherine Meyer, et al.
Published: (2022-10-01)
Intense PSMA Uptake in a Vertebral Hemangioma Mimicking a Solitary Bone Metastasis in the Primary Staging of Prostate Cancer via <sup>68</sup>Ga-PSMA PET/CT
by: Farid Gossili, et al.
Published: (2023-05-01)
by: Farid Gossili, et al.
Published: (2023-05-01)
Optimization of Automated Radiosynthesis of Gallium-68-Labeled PSMA11 with Two [<sup>68</sup>Ge]Ge/[<sup>68</sup>Ga]Ga Generators: Fractional Elution or Prepurification?
by: Flore Durieux, et al.
Published: (2023-11-01)
by: Flore Durieux, et al.
Published: (2023-11-01)
Optimized <sup>68</sup>Ga-Labeled Urea-Based PSMA-Targeted PET Tracers for Prostate Cancer
by: Yitian Wu, et al.
Published: (2022-08-01)
by: Yitian Wu, et al.
Published: (2022-08-01)
Single-Center Comparison of [<sup>64</sup>Cu]-DOTAGA-PSMA and [<sup>18</sup>F]-PSMA PET–CT for Imaging Prostate Cancer
by: Siroos Mirzaei, et al.
Published: (2021-10-01)
by: Siroos Mirzaei, et al.
Published: (2021-10-01)
Diagnostic Impact of Dual-Time PET/CT with <sup>68</sup>Gallium-PSMA in Prostate Cancer and <sup>68</sup>Gallium-DOTATOC in Neuroendocrine Tumors
by: Damiano Librizzi, et al.
Published: (2023-03-01)
by: Damiano Librizzi, et al.
Published: (2023-03-01)
Sublingual Atropine Administration as a Tool to Decrease Salivary Glands’ PSMA-Ligand Uptake: A Preclinical Proof of Concept Study Using [<sup>68</sup>Ga]Ga-PSMA-11
by: Vincent Nail, et al.
Published: (2022-06-01)
by: Vincent Nail, et al.
Published: (2022-06-01)
[<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Prior Indetermined Findings on [<sup>18</sup>F]PSMA-1007 Imaging
by: Moritz B. Bastian, et al.
Published: (2024-10-01)
by: Moritz B. Bastian, et al.
Published: (2024-10-01)
Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with <sup>177</sup>Lu-PSMA and Combined <sup>225</sup>Ac- and <sup>177</sup>Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation
by: Thomas Langbein, et al.
Published: (2022-08-01)
by: Thomas Langbein, et al.
Published: (2022-08-01)
[68Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [177Lu]Lu-PSMA therapy in relapsing high-grade glioma
by: Peter Truckenmueller, et al.
Published: (2022-09-01)
by: Peter Truckenmueller, et al.
Published: (2022-09-01)
Differences in Distribution and Detection Rate of the [<sup>68</sup>Ga]Ga-PSMA Ligands PSMA-617, -I&T and -11—Inter-Individual Comparison in Patients with Biochemical Relapse of Prostate Cancer
by: Falk Gühne, et al.
Published: (2021-12-01)
by: Falk Gühne, et al.
Published: (2021-12-01)
Evaluation of Cyclotron Solid Target Produced Gallium-68 Chloride for the Labeling of [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>68</sup>Ga]Ga-DOTATOC
by: Michał Jagodziński, et al.
Published: (2025-08-01)
by: Michał Jagodziński, et al.
Published: (2025-08-01)
Diagnostic Role of <sup>18</sup>F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review
by: Salam Awenat, et al.
Published: (2021-03-01)
by: Salam Awenat, et al.
Published: (2021-03-01)
<sup>68</sup>Ga-PSMA-11 PET/CT Initial Staging in Black and White South African Males with ISUP Grade Group 1 and 2 Prostate Adenocarcinoma
by: Letjie C. Maserumule, et al.
Published: (2022-04-01)
by: Letjie C. Maserumule, et al.
Published: (2022-04-01)
Competition (‘Steal’ Phenomenon) between [<sup>68</sup>Ga]Ga-PSMA-11 Uptake in Prostate Tumor Tissue Versus Healthy Tissue
by: Esmée C. A. van der Sar, et al.
Published: (2021-05-01)
by: Esmée C. A. van der Sar, et al.
Published: (2021-05-01)
A Specific HPLC Method to Determine Residual HEPES in [<sup>68</sup>Ga]Ga-Radiopharmaceuticals: Development and Validation
by: Silvia Migliari, et al.
Published: (2022-07-01)
by: Silvia Migliari, et al.
Published: (2022-07-01)
Response Assessment and Prediction of Progression-Free Survival by <sup>68</sup>Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Fadi Khreish, et al.
Published: (2021-07-01)
by: Fadi Khreish, et al.
Published: (2021-07-01)
Synthesis of DOTA-Based <sup>43</sup>Sc Radiopharmaceuticals Using Cyclotron-Produced <sup>43</sup>Sc as Exemplified by [<sup>43</sup>Sc]Sc-PSMA-617 for PSMA PET Imaging
by: Jason P. Meier, et al.
Published: (2025-06-01)
by: Jason P. Meier, et al.
Published: (2025-06-01)
Synthesis and Preclinical Evaluation of Two Novel <sup>68</sup>Ga-Labeled Bispecific PSMA/FAP-Targeted Tracers with 2-Nal-Containing PSMA-Targeted Pharmacophore and Pyridine-Based FAP-Targeted Pharmacophore
by: Arsyangela Verena, et al.
Published: (2024-02-01)
by: Arsyangela Verena, et al.
Published: (2024-02-01)
The Value of <sup>68</sup>Ga-PSMA PET/CT Following Equivocal <sup>18</sup>F-NaF PET/CT in Prostate Cancer Patients
by: Claus Madsen, et al.
Published: (2020-05-01)
by: Claus Madsen, et al.
Published: (2020-05-01)
Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET/CT with an inter- and intrapatient based analysis
by: Cristina E. Popescu, et al.
Published: (2024-04-01)
by: Cristina E. Popescu, et al.
Published: (2024-04-01)
Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy
by: Dheeratama Siripongsatian, et al.
Published: (2024-10-01)
by: Dheeratama Siripongsatian, et al.
Published: (2024-10-01)
Advances in <sup>177</sup>Lu-PSMA and <sup>225</sup>Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Sui Wai Ling, et al.
Published: (2022-10-01)
by: Sui Wai Ling, et al.
Published: (2022-10-01)
[<sup>99m</sup>Tc]Tc-PSMA-T4—Novel SPECT Tracer for Metastatic PCa: From Bench to Clinic
by: Michał Maurin, et al.
Published: (2022-10-01)
by: Michał Maurin, et al.
Published: (2022-10-01)
An Innovative Approach with [<sup>68</sup>Ga]Ga-PSMA PET/CT: The Relationship Between PRIMARY Scores and Clinical and Histopathological Findings
by: Gozde Mutevelizade, et al.
Published: (2025-07-01)
by: Gozde Mutevelizade, et al.
Published: (2025-07-01)
<sup>177</sup>Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
by: Yasemin Sanli, et al.
Published: (2021-04-01)
by: Yasemin Sanli, et al.
Published: (2021-04-01)
Similar Items
-
Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System
by: Zsófia Sára Mikó, et al.
Published: (2024-10-01) -
<sup>68</sup>Ga-PSMA PET/CT in Recurrent Prostate Cancer after Radical Prostatectomy Using PSMA-RADS Version 2.0
by: Gabriele Masselli, et al.
Published: (2024-06-01) -
PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression
by: Florian Rosar, et al.
Published: (2022-05-01) -
[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2021-07-01) -
Imageological/Structural Study regarding the Improved Pharmacokinetics by <sup>68</sup>Ga-Labeled PEGylated PSMA Multimer in Prostate Cancer
by: Huihui Zhang, et al.
Published: (2023-04-01)
